F S&P 500
5,107.00 +15.50 (+0.30%) F Dow Jones
38,614.00 +232.00 (+0.60%) F Nasdaq
17,765.25 +115.50 (+0.65%) E-mini Russell 2000 Index Futur
2,023.20 -4.00 (-0.20%) Petróleo
79.08 +0.13 (+0.16%) Oro
2,309.70 +0.10 (+0.00%)
Astellas Pharma Inc. (ALPMF)
Astellas Pharma Inc.
2-5-1, Nihonbashi-Honcho
Chuo-Ku
Tokyo 103-8411
Japan
81 3 3244 3000
https://www.astellas.com
Sector(es): Healthcare
Industria: Drug Manufacturers - General
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Naoki Okamura BSc | President, CEO & Director | 937.47k | N/D | 1962 |
| Mr. Atsushi Kitamura | Chief Financial Officer | N/D | N/D | N/D |
| Nobue Yasuda | General Manager of Finance & Accounting Department | N/D | N/D | N/D |
| Mr. Yoshitsugu Shitaka Ph.D. | Chief Scientific Officer & Senior Managing Executive Officer | N/D | N/D | N/D |
| Ms. Catherine B. Levitt | General Counsel | N/D | N/D | N/D |
| Mr. Katsuyoshi Sugita | Chief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director | N/D | N/D | 1967 |
| Mr. Stig Ogata | Vice President of Corporate Communications | N/D | N/D | N/D |
| Ms. Collette Taylor | Senior Vice President of Human Resources | N/D | N/D | 1963 |
| Ms. Tatjana Dragovic | Senior VP and Head of Ethics & Compliance | N/D | N/D | N/D |
| Mr. Nobuaki Tanaka | President of Japan Commercial & Senior Corporate Executive | N/D | N/D | N/D |
Descripción
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.
Gestión corporativa
La calificación ISS Governance QuickScore de Astellas Pharma Inc. a partir del 1 de mayo de 2024 es 2. Las puntuaciones principales son Auditoría: 1; Junta: 2; Derechos del accionista: 6; Compensación: 1.
